Trial Profile
A Phase 1, Open-label, Multi-center, Dose-escalation Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of ISU304 in Previously Treated Hemophilia B Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Jun 2023
Price :
$35
*
At a glance
- Drugs Dalcinonacog alfa (Primary) ; Dalcinonacog alfa (Primary) ; Nonacog alfa (Primary)
- Indications Haemophilia B
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors ISU Abxis
- 12 Jun 2023 Results supporting dosing regimen selection in adults and perform first in paediatric dose extrapolations using a model based pharmacokinetic (PK) approach of population PK model built using adult data from NCT03186677and NCT03995784, published in the Advances in Therapy
- 04 Feb 2021 Results published in the Journal of Thrombosis and Haemostasis
- 07 Mar 2019 Status changed from recruiting to completed, as reported in a Catalyst Biosciences media release.